ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study
Martin Reck, Koichi Hagiwara, Bao-Hui Han et al.
· 0 citations
We have 3 of 63 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Open access
Sep 2026
Osimertinib in advanced non-small cell lung cancer (NSCLC) harboring different EGFR uncommon variants: real-world data from the Italian biomarker ATLAS database
Osimertinib exhibited meaningful differences in efficacy and resistance mechanisms across distinct ucEGFR mut, and ex19 delins showed comparable survival outcomes and resistance patterns to classical ex19 deletions, albeit with heterogeneous osimertinib sensitivity depending on the deletion–insertion starting codon.
G. Farinea, A. Mogavero, A. Vitale et al.
· ESMO Open · 0 citations
Open access
Jul 2026
Germline determinants of risk and molecular subtype in young-onset lung cancer
A complex germline architecture underlying susceptibility and molecular subtype in young-onset lung cancer is delineated, consistent with additive risk from rare and common variants.
J. LoPiccolo, Ryan L. Collins, Noah Fields et al.
· medRxiv · 0 citations